- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Adam Simmons Outlines Efficacy of ALKS 3831 Across Subgroups of Patients With Schizophrenia
Adam Simmons, director of clinical program management, Alkermes, interviewed at the American Psychiatric Association Annual Meeting, discussed the efficacy of the investigational drug ALKS 3831 (olanzapine/samidorphan) in various patient populations.
Adam Simmons, director of clinical program management, Alkermes, interviewed at the American Psychiatric Association Annual Meeting, discussed the efficacy of the investigational drug ALKS 3831 (olanzapine/samidorphan) in various patient populations.
Transcript
What can the data presented at APA tell us about the effectiveness of ALKS 3831 compared with olanzapine across subgroups of patients?
In the data that we’re presenting here at the APA conference, what it is that we’ve shown is that the antipsychotic efficacy of olanzapine when combined with samidorphan is very similar across 3 different patient populations. One in patients that were treated in an outpatient basis; one in patients that were treated in an outpatient basis combined with schizophrenia and alcohol use disorder, and the third study we had looked at people who were acutely psychotic having an acute exacerbation of schizophrenia and comparing 3831 to placebo with olanzapine as a comparator. In that third study where we were specifically looking at antipsychotic efficacy, we did look at subgroups. We’re planning on presenting that data and describing it more in a manuscript that’ll be published in the future.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
